{
    "relation": [
        [
            "",
            "Liraglutide -> Liraglutide -> Liraglutide",
            "Exenatide -> Liraglutide -> Liraglutide"
        ],
        [
            "Description",
            "Liraglutide 1.8 mg once daily + OAD (metformin monotherapy, sulphonylurea (SU) monotherapy or a combination), Weeks 0-26 (double-blinded) continued to receive liraglutide 1.8 mg once daily + OAD in extension period (weeks 26-52 and 52-78)",
            "Exenatide 10 mcg twice daily + OAD (metformin monotherapy, sulphonylurea (SU) monotherapy or a combination), Weeks 0-26 (double-blinded) switched to receive liraglutide 1.8 mg once daily + OAD in extension period (weeks 26-52 and 52-78)"
        ]
    ],
    "pageTitle": "Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00518882?sect=Xi015&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042989826.86/warc/CC-MAIN-20150728002309-00197-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 874102323,
    "recordOffset": 874083648,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups Eligible subjects were subjects with type 2 diabetes being treated with oral anti-diabetic (OAD) therapy(ies) for at least 3 months prior to the study. Three subjects were exposed to study drug prior to randomisation, and thus only included in safety analysis set. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details A total of 133 centres in 15 countries: Austria (4), Denmark (6), Finland (5), France (5), Germany (14), Ireland (4), Macedonia (1), Norway (4), Poland (9), Romania (3), Slovenia (3), Spain (4), Sweden (2), Switzerland (4) and United States (65). Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: liraglutide Drug: exenatide Interventions:",
    "textAfterTable": "Participant Flow for 2 periods Period 1: \u00a0 Double-Blind, Week 0-26 \u00a0 \u00a0 Liraglutide -> Liraglutide -> Liraglutide \u00a0 \u00a0 Exenatide -> Liraglutide -> Liraglutide \u00a0 STARTED \u00a0 \u00a0 235 [1] \u00a0 232 [2] Randomised \u00a0 \u00a0 233 \u00a0 \u00a0 231 \u00a0 COMPLETED \u00a0 \u00a0 202 \u00a0 \u00a0 187 \u00a0 NOT COMPLETED \u00a0 \u00a0 33 \u00a0 \u00a0 45 \u00a0 Adverse Event \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 23 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 31 \u00a0 Lack of Efficacy \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 1 \u00a0",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}